Serina's SER-252 Phase 1b Cohort 1 clears safety review; advances to Cohort 2

Serina Therapeutics, Inc.

Independent Safety Monitoring Committee recommended advancing SER-252 to Cohort 2 after blinded review of Cohort 1 safety/tolerability data.
Cohort 1 (lowest dose, n=8) showed sustained apomorphine exposure and motor function improvements in individual patients.
Topline data from single-ascending-dose portion expected in first half of 2027.
Study is randomized, double-blind, placebo-controlled; 5 cohorts of 8 in SAD portion, then MAD portion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.